Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | Euronext Growth Oslo |
Sektor | Hälsovård |
Industri | Medicinteknik |
2021-07-02 13:39:30
With reference to the stock exchange announcement on March 29, 2021, SoftOx has
now submitted a new application for national approval of its biocidal products
in Norway. The application addresses the objections raised in the first
application and only applies to the Norwegian market.
"The company experienced that the previous application involving Norway, Sweden
and Denmark entailed great procedural complexity, which we consider to be a
contributing factor to the application being rejected. The new improved
application now addresses the weaknesses that were commented on in the previous
application. New applications to other countries will be submitted on an
ongoing basis. In addition, SoftOx has appealed the rejection of the first
application." says CEO Geir Almås.
For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599
About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth
Oslo. Our vision is "Helping the world fighting infections - developing new ways
of eradicating infections and fighting antimicrobial resistance". We are working
to combat major threats to human health, namely the emergence of antimicrobial
resistance (AMR), biofilm infections in chronic wounds and the spread of
viruses. For more information on SoftOx, visit www.soft-ox.com.